Press Releases
U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients...
This acceptance for review marks the first in the U.S. for a SLAMF7-directed immunostimulatory antibody "AbbVie is encouraged by the FDA’s decision to award priority review to this application" Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie...
Press Releases
Lilly To Participate In Morgan Stanley Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015. Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology and Richard Gaynor, M.D., senior vice president of product...
Press Releases
Lilly, AACE Mark 10th Anniversary Of Hurricane Katrina With Reminder Of “My Diabetes Emergency Plan” Checklist
The checklist, now in its ninth year, is a direct result of post-Katrina learnings ,For Sherry Martin, M.D., starting her new job at Eli Lilly and Company (NYSE: LLY) in August 2005 was stressful enough. ...
Press Releases
U.S. District Court Rules In Lilly’s Favor On Alimta Vitamin Regimen Patent
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). ...
Press Releases
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant...
Press Releases
Jardiance® Demonstrated Cardiovascular (CV) Risk Reduction In People With Type 2 Diabetes At High Risk For CV Events
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes...
Press Releases
Lilly’s Humalog® 200 Units/ML KwikPen® Now Available In U.S. Pharmacies
First and only concentrated mealtime insulin analog may help people with diabetes fit their treatment into their daily lives Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S.,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















